ITIL-306 in Advanced Lung Adenocarcinoma

• Research type

  Research Study

• Full title

  A Phase 1a/1b, Open-Label, Multicentre Study Evaluating the Safety and Feasibility of ITIL-306 in Subjects with Advanced Lung Adenocarcinoma

• IRAS ID

  1007928

• Contact name

  Robert Hawkins

• Contact email

  robert.hawkins@instilbio.com

• Sponsor organisation

  Instil Bio (UK) Ltd

• Research summary

  Instil Bio is investigating a phase 1a/1b, open-label, multicentre study to test the safety of a genetically engineered product made from the patient's own white blood cells (tumour infiltrating lymphocyte, TIL) found in the tumour. The product, ITIL-306, specifically targets a tumour protein known as folate receptor, and therefore improves tumour killing. The study will recruit adults with advanced adenocarcinoma of the lung.
  Participants will sign a consent form, undergo procedural requirements and receive protocol-specified treatment (Screening, Surgery, Chemotherapy, ITIL-306 infusion, inpatient stay and follow up visits).

• REC name

  North East - York Research Ethics Committee

• REC reference

  23/NE/0134

• Date of REC Opinion

  21 Sep 2023

• REC opinion

  Further Information Favourable Opinion